- Home
- BTAI vs NRBO Comparison
BTAI vs NRBO Comparison
Compare BTAI & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NRBO
- Stock Information
- Founded
- BTAI 2017
- NRBO N/A
- Country
- BTAI United States
- NRBO United States
- Employees
- BTAI N/A
- NRBO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- NRBO Health Care
- Exchange
- BTAI Nasdaq
- NRBO Nasdaq
- Market Cap
- BTAI 28.7M
- NRBO 27.9M
- IPO Year
- BTAI 2018
- NRBO N/A
- Fundamental
- Price
- BTAI $0.57
- NRBO $2.19
- Analyst Decision
- BTAI Strong Buy
- NRBO Strong Buy
- Analyst Count
- BTAI 4
- NRBO 1
- Target Price
- BTAI $5.00
- NRBO $10.00
- AVG Volume (30 Days)
- BTAI 458.6K
- NRBO 35.2K
- Earning Date
- BTAI 11-14-2024
- NRBO 11-07-2024
- Dividend Yield
- BTAI N/A
- NRBO N/A
- EPS Growth
- BTAI N/A
- NRBO N/A
- EPS
- BTAI N/A
- NRBO N/A
- Revenue
- BTAI $2,276,000.00
- NRBO N/A
- Revenue This Year
- BTAI $247.03
- NRBO N/A
- Revenue Next Year
- BTAI $88.16
- NRBO N/A
- P/E Ratio
- BTAI N/A
- NRBO N/A
- Revenue Growth
- BTAI 83.25
- NRBO N/A
- 52 Week Low
- BTAI $0.50
- NRBO $2.08
- 52 Week High
- BTAI $4.32
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- BTAI 43.77
- NRBO 31.67
- Support Level
- BTAI $0.50
- NRBO $2.37
- Resistance Level
- BTAI $0.72
- NRBO $2.99
- Average True Range (ATR)
- BTAI 0.08
- NRBO 0.31
- MACD
- BTAI -0.01
- NRBO -0.03
- Stochastic Oscillator
- BTAI 20.70
- NRBO 0.62
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.